The outcome of ovulation induction in anovulatory polycystic ovarian syndrome (PCOS) may depend, in part, on the pharmacologic compounds used, but also on individual patient characteristics, such as age, body mass index (BMI), hyperandrogenism, luteinizing hormone (LH), hyper-secretion, anti mullerian hormone (AMH) levels and possibly antral follicle count (AFC) with ovarian volume of these wom...

In addition to causing regression of the Mullerian duct in the male embryo, Mullerian Inhibiting Substance (MIS) inhibits the growth of epithelial ovarian cancer cells, which are known to be of Mullerian origin. Because the uterine cervix is derived from the same Mullerian duct precursor as the epithelium of the ovary, we tested the hypothesis that cervical cancer cells might also respond to MI...

Subjects/Discussion. Two cases of clinical and radiological response of recurrent mixed Mullerian tumours following treatment with either nasal (Buserilin) or intramuscular (Goserilin) GnRH analogues are reported and a short review of the evidence to support this treatment option presented.

BACKGROUND Mc Indoe vaginoplasty is one of the mostly performed surgical interventions in Mullerian agenesis. CASE PRESENTATIONS We present our experience on the use of a new designed vaginal stent that was coated with silicone in two mullerian agenesis cases who had Mc Indoe vaginoplasty. Both full thickness and splitt thickness skin graft were used with the stent. No graft loss or hyperthro...

Mullerian Inhibiting Substance (MIS) functions to promote regression of the Mullerian duct during male development. Maintaining the sexually dimorphic pattern of MIS expression is essential for proper mammalian reproductive tract development. Here, we show that the intricate spatial and temporal pattern of MIS expression is directed by a remarkably small proximal promoter of only 180 base pairs...